


 Cite this: *RSC Adv.*, 2019, **9**, 16729

DOI: 10.1039/c9ra90039j


www.rsc.org/advances

Correction: Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer

 Changliang Liu,^{ac} Hongyang Duan,^{ab} Zijian Zhao,^a Wenzhe Li,^{ab} Lilusi Ma,^a Xiaocui Fang,^{*a} Chen Wang^{*ac} and Yanlian Yang^{*ac}

 Correction for 'Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer' by Changliang Liu *et al.*, *RSC Adv.*, 2018, **8**, 39948–39956.

The authors regret that the term "CXCL12" was incorrectly displayed as "CXCR12" in Scheme 1 and Fig. 6(a)–(c) in the original article. The correct versions of Scheme 1 and Fig. 6(a)–(c) are presented below.



Scheme 1 Schematic illustration of the preparation of the $\text{P}_{\text{Ac}80}$ –E5 complex and the process of anti-tumor metastasis of the E5 peptide in the presence of $\text{P}_{\text{Ac}80}$.




Fig. 6 (a–c) The inhibitory effect of E5 and $\text{P}_{\text{Ac}80}$ –E5 on: (a) MCF-7; (b) MDA-MB-231; and (c) 4T1 cells detected by transwell assay. The CXCL12 supplemented sample without E5 or $\text{P}_{\text{Ac}80}$ –E5 was set as 100% as the control. Error bars represent the standard deviation ($n = 3$).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aCAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, P. R. China. E-mail: fangxc@nanoctr.cn; wangch@nanoctr.cn; yangyl@nanoctr.cn; Tel: +86-10-82545561; +86-10-82545559

^bAcademy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, P. R. China

^cUniversity of Chinese Academy of Sciences, Beijing 100049, P. R. China